Systemic Bio Emerges as a Top Finalist for Prestigious Award
HOUSTON — Systemic Bio™, a trailblazer in bioprinting technology and a subsidiary of 3D Systems, has achieved a remarkable milestone by becoming a Top 10 Finalist for the coveted SLAS 2025 Innovation Award. This accolade highlights the transformative potential of Systemic Bio's proprietary h-VIOS™ platform, which accelerates the process of drug discovery and development through the use of relevant human data obtained from bioprinted tissues.
Understanding the Significance of the SLAS Innovation Award
The SLAS Innovation Award is presented annually at the SLAS International Conference and Exhibition, a meeting that gathers leaders in laboratory science and automation. This award recognizes pioneering technologies that are expected to significantly influence laboratory practices. Systemic Bio's innovative platform, which utilizes advanced bioprinting techniques to create intricate vascularized tissue models, has garnered significant attention leading to this recognition.
CEO Taci Pereira on the Achievement
CEO Taci Pereira expressed her excitement regarding this recognition, stating, "We are thrilled to be recognized by SLAS as a Top 10 Finalist for their esteemed Innovation Award. This acknowledgment reflects the hard work and ingenuity of our team and highlights the transformative power of our platform in driving innovation within the pharmaceutical industry. By providing more accurate and predictive tools, we aim to accelerate the development of safer and more effective therapies for patients worldwide.”
Systemic Bio's Role in Drug Development
Systemic Bio’s h-VIOS platform represents a revolutionary change in the approach to drug development. It addresses long-standing challenges found in preclinical testing by producing bioprinted tissue models that simulate human organ systems with unprecedented precision. These models, generated in Houston from a cutting-edge facility with an ISO 7 clean room, enable Systemic Bio to produce thousands of tissue models as part of its Quality Management System (QMS).
Powering Collaborative Efforts
These advanced tissue models play a crucial role in Systemic Bio’s ongoing development endeavors, empowering collaborations with leading pharmaceutical companies. This collaborative synergy aims to enhance the development of new medical therapies and ensure that they are more relevant to human health and physiology.
Presentation at the SLAS Conference
As a recognition of its innovative technology, Systemic Bio will present its findings and procedures in a session titled “h-VIOS: A human-relevant drug discovery and development platform using bioprinted human tissues,” scheduled for a Monday slot at the SLAS Conference in San Diego. This presentation will take place from 4:00 - 4:30 p.m. Pacific Standard Time, a pivotal moment to showcase its cutting-edge capabilities.
Systemic Bio's Mission and Technology
Founded as a wholly-owned subsidiary of 3D Systems, Systemic Bio is dedicated to revolutionizing drug discovery and development. Utilizing human-relevant data and proprietary bioprinted vascularized organ models, Systemic Bio aims to enhance the efficiency of drug development processes. This innovative technology harnesses 3D Systems’ production-level bioprinting capabilities, allowing the company to create highly precise models of both healthy and diseased tissues using biomaterials and human cells.
Leveraging Data for Better Outcomes
The fabricated organs-on-chips produced by Systemic Bio can be manufactured consistently in large quantities, enabling the testing of pharmaceutical compounds early in the development process. These systems are not only effective for research but also integrate machine learning to produce significant human-relevant insights concerning potential therapeutic outcomes.
Extending Industry Knowledge and Collaboration
As Systemic Bio progresses in its mission, it continuously seeks to expand its knowledge and resources within the biotech industry. The team’s focus on innovation, collaboration, and data-driven solutions places them at the forefront of advancements in healthcare.
Frequently Asked Questions
What is Systemic Bio known for?
Systemic Bio is renowned for its pioneering bioprinting technology that accelerates drug discovery and development through human-relevant tissue models.
What distinguishes the h-VIOS platform?
The h-VIOS platform utilizes advanced bioprinting methods to produce precise vascularized tissue models that closely mimic human organ systems.
How does Systemic Bio contribute to the pharmaceutical industry?
By providing innovative tissue models, Systemic Bio enhances preclinical testing, leading to faster and safer drug development.
What recognition has Systemic Bio recently received?
Systemic Bio has been named a Top 10 Finalist for the SLAS 2025 Innovation Award, acknowledging its groundbreaking technological advancements.
Where can I find more information about Systemic Bio?
More details about Systemic Bio and its cutting-edge technologies can be found on its official website, www.systemic.bio.
